Azacitidine

The PBS subsidises azacitidine for patients with myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with azacitidine under the National Health Act 1953, section 100 for patients with myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing azacitidine.

Section 100 arrangements

This item is only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

You must include the hospital name and provider number on the authority application form. This item isn’t PBS subsidised for hospital in-patients.

Authority Applications

Applying for initial treatment

Apply for initial authority approval to prescribe initial PBS subsidised azacitidine to treat myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised azacitidine to treat myelomonocytic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 November 2020